Site icon pharmaceutical daily

Global Systemic Lupus Erythematosus (SLE) Market Report 2022: Expected Value of $2.71 Billion by 2026, Growing from $1.89 Billion – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Systemic Lupus Erythematosus (SLE) Market: Analysis By Product Type, By Route of Administration, By End User, By Region Size and Trends with Impact of COVID-19 and forecast up to 2026” report has been added to ResearchAndMarkets.com’s offering.

In 2021, the global systemic lupus erythematosus market was valued at US$1.89 billion. The market is projected to reach US$2.71 billion by 2026. The systemic lupus erythematosus market is expected to grow at a CAGR of 7.49% over the forecasted years 2022-2026.

SLE is a very undertreated disease with limited effective therapeutic options globally. The only available biologic therapy approved in this indication globally are GSK’s Benlysta (approved by US FDA 2011 and China’s NMPA in 2019), Astra Zeneca’s Saphnelo (approved by the FDA in August 2021) and RemeGen’s telitacicept (approved by China’s NMPA in 2021). However, with significant unmet medical need, the market would grow in the years to come.

Market Segmentation Analysis:

Market Dynamics:

Key Players:

Key Topics Covered:

1. Executive Summary

2. Introduction

2.1 Systemic Lupus Erythematosus (SLE): An Overview

2.2 Systemic Lupus Erythematosus (SLE) Segmentation: An Overview

3. Global Market Analysis

4. Regional Market Analysis

5. Impact of COVID-19

6. Market Dynamics

6.1 Growth Drivers

6.1.1 Increasing Healthcare Expenditure

6.1.2 Increasing Female Population

6.1.3 Rapid Urbanization

6.1.4 Favorable Government Initiatives

6.1.5 Rising Prevalence of SLE Disease

6.2 Challenges

6.2.1 Stringent Regulatory Environment

6.2.2 High Cost of Drug Development

6.3 Trends

6.3.1 Rising Clinical Trials

6.3.2 Adoption of Stem Cell Therapy

6.3.3 Rising Awareness Among People

7. Competitive Landscape

7.1 The US and China Systemic Lupus Erythematosus Market Players by Marketed Biologics for SLE Treatment

7.2 The US and China Systemic Lupus Erythematosus Market players by Pipeline Biologics for SLE Treatment

For more information about this report visit https://www.researchandmarkets.com/r/sefkto

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version